KIYATEC Announces Addition of Capital Health as Clinical Site in Trial to Predict GBM Patient-Specific Response to Cancer Drugs Prior to Treatment

On August 13, 2019 KIYATEC, Inc. reported that Capital Health has joined its U.S. clinical trial, 3D-PREDICT, to validate the company’s test as a patient-specific predictor of response to cancer therapies in glioblastoma (GBM) and anaplastic astrocytoma (AA) patients (Press release, KIYATEC, AUG 13, 2019, View Source [SID1234538655]). Capital Health is currently the only healthcare system in New Jersey, Pennsylvania and the New York City region enrolling GBM patients in the study.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"Capital Health is committed to improving the health and well-being of our patients, while making the care we provide as personalized as possible. Taking part in this clinical trial underscores our mission to provide the best care, for each individual patient, at the earliest possible time," said Dr. Navid Redjal, director of Neurosurgical Oncology at Capital Health, and lead investigator of the study. "In oncology treatment, and especially for our patients with glioblastoma, being able to predict if a treatment will be successful has the potential to truly change patient care, particularly when time is of the essence."

3D-PREDICT is a prospective, open-label, multi-institutional, non-interventional study to validate KIYATEC’s EV3D platform for clinical use and to investigate the impact on outcomes for cancer patients with both newly diagnosed and recurrent epithelial ovarian cancer and recurrent high-grade gliomas. KIYATEC’s EV3D cell culture platform utilizes live cancer cells derived from surgical or biopsy tissue to create a patient specific in vivo-like tumor and immune microenvironment. The tumor and immune microenvironment are used to accurately model and assess responses from both investigational and approved cancer therapies. The study is anticipated to continue through 2020. Details on the trial can be found on View Source

"The continued growth of patient enrollment with the addition of Capital Health is a true testament to the value that oncology clinical teams realize in being able to better determine a viable treatment path for their patients at the earliest possible time," said Matthew Gevaert, CEO of KIYATEC. "We are realizing tremendous momentum, both with our ongoing clinical trial as well as recent publication of the positive results of our ovarian cancer study in the Nature journal Scientific Reports. This is a truly exciting time in the company’s growth as we continue on our path to provide a more personalized cancer treatment experience for patients."